Verrica Pharmaceuticals Inc. (VRCA)

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. develops and commercializes medications for dermatologic diseases, including skin cancers. Its main product, YCANTH (VP-102), is an FDA-approved topical treatment for molluscum in patients aged two years and older, and it is also being developed for common warts. The company is advancing VP-315, an injectable therapy, for the treatment of basal cell carcinoma and other dermatologic oncology conditions.

Snapshot

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

Peer comparison

Where Verrica Pharmaceuticals’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Verrica Pharmaceuticals’s long-term debt to equity of 0.00 ranks in the 1st percentile of the 64 pharmaceutical companies reporting it. Verrica Pharmaceuticals’s revenue growth of +370.2% ranks in the 91st percentile of the 187 pharmaceutical companies reporting it. Verrica Pharmaceuticals’s FCF margin of -49.5% ranks in the 10th percentile of the 110 pharmaceutical companies reporting it.

6 reported insider purchases (code P) totaling $210,890 in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 2 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4. Multiple insiders have bought recently (a cluster buy).

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Quarterly trend (as reported)

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

Selected SEC filings

Largest pharmaceutical peers

All pharmaceutical stocks →All Healthcare companies →